Sinopharm vaccine is effective against more than 10 types of metabolic viruses

vaccine is effective against more than 10 types of metabolic viruses

China has injected 102 million doses of COVID-19 vaccine as of March 27, the National Health Commission (NHC) said on Sunday. While the global supply of two-dose vaccines developed by China’s Sinopharm has exceeded 100 million doses. Fifty countries and regions have approved Sinopharm vaccines for immediate use. Mr. Wu Liangyou, deputy director of the NHC’s disease control bureau, said China was expanding its vaccination plan to build a wider immune system.

The plan focuses on key groups, including people living in large or medium-sized cities, port cities or border areas, employees of state-owned enterprises, college students and professors, and supermarket staffs. People over the age of 60 or with a chronic illness can also be protected from the virus. The second dose should be given within three to eight weeks after the first injection, Wang Huaqing, director of immunization planning at the China Center for Disease Control and Prevention, told a news conference on Sunday. People are advised to receive only two doses of the vaccine, Wang said. Those who are eligible for the vaccine should be vaccinated as soon as possible to develop their immunity.

Meanwhile, Zhang Yuntao, vice president of China National Biotec Group, which is affiliated with Sinopharm, said that the Sinopharm vaccine has been shown to be effective against more than 10 mutation viruses found in the United Kingdom and South Africa and other areas.

Mr. Zhang said further tests are underway in relation to the mutation virus found in Brazil and Zimbabwe. Research data on children, aged 3 to 17, showed the expected results, suggesting that the group could be included in future vaccination plans.